The APPLE trial is a multicentre, 3-arm, phase II study evaluating a ctDNA test specific for T790M on a cohort of treatment-naïve EGFR-mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.